机译:从炎症性肠病患者中从英夫利昔单抗创新者转换为生物素线:一个12个月的多长期观测前瞻性队列研究
Clinical LaboratoryMáxima Medical CenterVeldhoven The Netherlands;
Department of GastroenterologyMáxima Medical CenterEindhoven and Veldhoven The Netherlands;
Department of GastroenterologyMáxima Medical CenterEindhoven and Veldhoven The Netherlands;
Department of Clinical PharmacyElkerliek HospitalHelmond The Netherlands;
Expert Center Clinical ChemistryEindhoven The Netherlands;
Expert Center Clinical ChemistryEindhoven The Netherlands;
Department of Clinical Pharmacy and PharmacologyMáxima Medical CenterVeldhoven The Netherlands;
Clinical LaboratoryMáxima Medical CenterVeldhoven The Netherlands;
Department of Clinical Pharmacy and PharmacologyMáxima Medical CenterVeldhoven The Netherlands;
机译:从炎症性肠病患者中从英夫利昔单抗创新者转换为生物素线:一个12个月的多长期观测前瞻性队列研究
机译:治疗药物监测(TDM)作为从英夫利昔单抗创新者到风湿病患者生物仿生的工具的工具:12个月的观察前瞻性队列研究结果
机译:Prosit-Bio Cohort:用英夫利昔单抗治疗炎症性肠病患者的前瞻性观察研究
机译:用于炎症性肠病infliximab的适应症
机译:生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者:加拿大分析
机译:从英夫利昔单抗发起者切换到炎症性肠病中的SB2生物仿真:多中心前瞻性实验研究
机译:P519从炎症肠疾病患者的参考incripiximab转换为CT-P13:12个月的Multicentre研究结果